Trial Profile
A Partial Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Anastrozole [MPI 674; Meditrina], an Aromatase Inhibitor, on Endometrial Thickness in Healthy Premenopausal Women When Dosed at Various Times During the Menstrual Cycle (Protocol M-001)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- Sponsors Meditrina Pharmaceuticals
- 06 Feb 2008 Status changed from recruiting to completed according to a Meditrina Pharmaceuticals media release.
- 12 Apr 2007 New trial record.